Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7339589 | 0.91 | MEN1 (0.57) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL424285 | 0.87 | HIF1A (0.59) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL31298063 | 0.86 | MEN1 (0.67) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL7974996 | 0.85 | HIF1A (0.58) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL7974997 | 0.85 | HIF1A (0.58) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL424284 | 0.85 | HIF1A (0.58) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL12846060 | 0.84 | HIF1A (0.64) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL11613463 | 0.83 | HIF1A (0.53) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 | |
| SCHEMBL6204342 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1CYP1A2CYP3A4TDP1 | |
| SCHEMBL12783382 | 0.83 | HIF1A (0.55) | KDM4EALDH1A1HIF1AHSD11B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1899318-A1 | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | AstraZeneca AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006137791-A1 | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | disclosed |
| US-5925655-A | NOVEL ISOINDOLONE DERIVATIVES FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS AND CANCER DIABETIC RETINOPATHY AND OTHER DISEASES | MERCK & CO., INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0901373-A4 | Alpha v Beta 3 ANTAGONISTS | MERCK & CO INC (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0901373-A1 | Alpha v Beta 3 ANTAGONISTS | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037655-A1 | αvβ3 ANTAGONISTS | MERCK & CO., INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | KDM4E 3223/4885ALDH1A1 467/4885HIF1A 1185/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | KDM4E 3223/4885ALDH1A1 467/4885HIF1A 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.